EP. 1: The Targeted Pulse: The FDA Grants MB-105 ODD, and AI Helps Distinguish HER2 0 From 1+ in Breast Cancer
The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.
EP. 2: The Targeted Pulse: The Latest FDA Actions Across Cancer Types and Exploring the Efficiency of Remote Pharmacists in Community Oncology
The FDA makes furthering moves in SCLC, ovarian, and breast cancers, and the value of remote clinical pharmacists is explored in community oncology.
EP. 3: The Targeted Pulse: Hot Off-The-Press Approvals and What to View from ASCO GU 2025
FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.
